Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases.
Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases.
复制标题
DOI：
10.1038/bjc.1991.146
复制
发表时间：
1991-04
影响因子：
8.8
通讯作者：
Roberts PJ
中科院分区：
文献类型：
--
作者：
Kuusela P;Haglund C;Roberts PJ
测定了185例消化道恶性肿瘤和123例消化道良性疾病患者血清中CA 242的水平。CA 242是一种新的糖类肿瘤标志物。胰腺癌和胆管癌患者中CA 242水平升高（大于20 U ml-1）的百分比较高（68%）。敏感性略低于CA 19-9（76%）和CA 50（73%）。另一方面，在良性胰腺和胆道疾病中，CA 242水平升高的频率低于CA 19-9和CA 50水平。55%的结直肠癌患者血清CA 242浓度升高。CA 242检测到的Dukes A-B癌（47%）多于CEA（32%），而CEA在Dukes C-D癌中更常升高（71% vs 59%）。CA 242轻度升高（ad 41 U ml-1）在10%的良性结直肠疾病患者。使用推荐的临界值，CA 50和CA 19-9的灵敏度低于CA 242。当使用基于相关良性结直肠疾病的截止水平时，这些标志物的敏感性相似，并且略高于CEA。不到一半的胃癌患者（44%）血清CA 242水平升高。CA 242是一种很有前途的新的肿瘤标志物，它可能在胰腺癌和胆管癌以及结直肠癌的诊断中具有额外的价值，并且可能在根治性手术后监测癌症患者中有用。
The levels of CA 242, a new tumour marker of carbohydrate nature, were measured in sera of 185 patients with malignancies of the digestive tract and of 123 patients with benign digestive tract diseases. High percentages of elevated CA 242 levels (greater than 20 U ml-1) were recorded in patients with pancreatic and biliary cancers (68%). The sensitivity was somewhat lower than that of CA 19-9 (76%) and CA 50 (73%). On the other hand, in benign pancreatic and biliary tract diseases the CA 242 level was less frequently elevated than the CA 19-9 and CA 50 levels. The serum CA 242 concentration was increased in 55% of patients with colorectal cancer. CA 242 detected more Dukes A-B carcinomas (47%) than CEA (32%), whereas CEA was more often elevated (71% vs 59%) in Dukes C-D carcinomas. CA 242 was slightly elevated (ad 41 U ml-1) in 10% of patients with benign colorectal diseases. CA 50 and CA 19-9 had lower sensitivities than CA 242 using the recommended cut-off values. When cut-off levels based on relevant benign colorectal diseases were used, the sensitivities of these markers were similar and somewhat higher than that of CEA. Less than half of patients with gastric cancer (44%) had an elevated CA 242 serum level. CA 242 is a promising new tumour marker, that may be of additional value in the diagnosis of pancreatic and biliary, as well as colorectal cancer, and may be useful in monitoring cancer patients after radical surgery.